GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones that ...

"These results underscore an important principle in automated insulin delivery, which is that the intelligence of the algorithm is what ultimately drives glycemic outcomes," said Principal ...

The MarketWatch News Department was not involved in the creation of this content. NORTHRIDGE, Calif., March 10, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a global leader in full stack ...

Medtronic has reported three milestones in the US, expanding access to its MiniMed 780G insulin delivery system for individuals with type 1 diabetes (T1D) and insulin-requiring type 2 diabetes (T2D).

Medtronic has earned FDA approval that will allow it to broaden the scope of its MiniMed 780G system portfolio. FDA has cleared Medtronic’s SmartGuard algorithm as an interoperable automated glycemic ...

MiniMed (NASDAQ: MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate ...

GALWAY, Ireland, Feb. 2, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice, and ...

NORTHRIDGE, Calif., March 10, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a global leader in full stack insulin delivery, today announced CE (Conformité Européenne) Mark for use of the ...

Medtronic plc MDT has begun the broad U.S. commercial rollout of the MiniMed 780G system integrated with Abbott’s ABT Instinct sensor, designed exclusively for MiniMed systems. Earlier this year, the ...